•  
  •  
  •  
  •  

2026-05-29 03:15:43

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • The Sukhjit Starch and Chemicals Ltd delivers a Revenue Growth of 16.89% QoQ in Q4 FY26 with Optimistic Outlook
  • Power and Instrumentation Gujarat Ltd receives additional work order worth Rs. 7.13 crore
  • Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility
  • Kissht delivers first results post-listing: FY26 PAT up 75% YoY to ₹281 Cr; AUM crosses ₹7,000 Cr milestone
  • Likhitha Infrastructure Ltd receives order worth Rs. 121.04 crores

Keywords Selected:  USFDA

Stock Report

  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad
  • Caplin Steriles Ltd gets USFDA approval for Calcium Gluconate Injection
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Solara announces successful closure of US FDA inspection of its Puducherry Facility with continued state of cGMP compliance
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Fingolimod Capsules, 0.5 mg
  • USFDA inspection at Rubicon Research Ltd's R&D Facility
  • Supriya Lifescience Receives USFDA EIR with VAI Classification for Maharashtra API Facility
  • Ajanta Pharma Ltd updates on USFDA inspection
  • USFDA Inspection at Innoxel Lifesciences Private Limited
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Indoco Remedies' testing facility completes US FDA PAI
  • Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg

Latest Post

  • The Sukhjit Starch and Chemicals Ltd delivers a Revenue Growth of 16.89% QoQ in Q4 FY26 with Optimistic Outlook
  • Power and Instrumentation Gujarat Ltd receives additional work order worth Rs. 7.13 crore
  • Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility
  • Kissht delivers first results post-listing: FY26 PAT up 75% YoY to ₹281 Cr; AUM crosses ₹7,000 Cr milestone
  • Likhitha Infrastructure Ltd receives order worth Rs. 121.04 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025